Female Hair Loss (Androgenic Alopecia): DHT, Estrogen, and Peptide Approaches

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Female androgenic alopecia is influenced by DHT and estrogen balance; while conventional treatments exist, emerging peptide therapies offer novel approaches to stimulate hair growth and improve scalp health.

Female pattern hair loss (FPHL), also known as female androgenic alopecia (AGA), is a common and distressing condition characterized by progressive thinning of hair, primarily over the crown and frontal scalp. Unlike male pattern baldness, FPHL rarely leads to complete baldness but significantly impacts self-esteem and quality of life. The pathophysiology is complex, involving genetic predisposition, hormonal influences (androgens and estrogens), and inflammation. Understanding the interplay of dihydrotestosterone (DHT), estrogen, and emerging peptide therapies is crucial for effective management.

The Role of Androgens: DHT and Follicular Miniaturization

Dihydrotestosterone (DHT), a potent metabolite of testosterone, is the primary androgen responsible for androgenic alopecia in genetically predisposed individuals. DHT binds to androgen receptors in susceptible hair follicles, leading to follicular miniaturization [1]. This process gradually replaces terminal hairs with vellus hairs, shortens the anagen (growth) phase, and eventually leads to dormant follicles. While women have lower testosterone levels, follicular sensitivity to androgens or local androgen imbalances can still cause FPHL. Conditions like Polycystic Ovary Syndrome (PCOS) can exacerbate FPHL, though many women with FPHL have normal circulating androgen levels [2].

Estrogen's Protective and Modulatory Role

Estrogen generally promotes hair growth and prolongs the anagen phase. This protective effect is evident during pregnancy, with higher estrogen levels leading to thicker hair, and postpartum shedding as levels decline. The balance between androgens and estrogens is critical for hair health.

Estrogen Receptors: Hair follicles contain estrogen receptors, allowing estrogen to directly influence follicular activity and counteract androgen effects.

Aromatase Activity: The enzyme aromatase, which converts androgens into estrogens, is more active in the frontal scalp of women. This may explain why FPHL typically presents as diffuse thinning rather than a receding hairline [3].

Menopause and Estrogen Decline: Post-menopause, declining estrogen can shift the androgen-estrogen balance, potentially worsening FPHL. Systemic estrogen therapy (as part of HRT) or anti-androgen medications may be considered in such cases [4].

Spironolactone: This anti-androgenic aldosterone antagonist (typically 50-200 mg/day) reduces DHT levels and blocks androgen receptors, improving hair density [5]. It is often used off-label.

Finasteride/Dutasteride: Low-dose finasteride (1.25-5 mg/day) or dutasteride (0.5 mg/day) can be considered off-label in postmenopausal women. They inhibit 5-alpha reductase, which converts testosterone to DHT. These are contraindicated in premenopausal women due to teratogenicity [6].

Copper Peptides (e.g., GHK-Cu): These peptides improve scalp circulation, reduce inflammation, and stimulate hair follicle growth by promoting collagen synthesis and acting as an antioxidant [7].

Growth Factor Peptides: Some peptides mimic natural growth factors, activating signaling pathways that stimulate hair follicle stem cells and prolong the anagen phase. Examples include those found in platelet-rich plasma (PRP) or exosome therapies [9].

Early Diagnosis is Key: Prompt evaluation by a dermatologist or trichologist is essential for accurate diagnosis and to rule out other causes of hair loss.

Combination Therapy: FPHL often responds best to a combination of therapies, such as topical minoxidil with an oral anti-androgen or adjunctive peptide treatments.

Patience is Required: Hair growth is a slow process. Visible improvements typically take 6-12 months of consistent treatment.

Address Underlying Conditions: If hyperandrogenism is present (e.g., due to PCOS), managing the underlying condition is crucial for successful FPHL treatment.

Holistic Approach: Nutritional support, stress management, and gentle hair care practices complement medical treatments.

References

[1] Cleveland Clinic. (n.d.). DHT (Dihydrotestosterone): What It Is, Side Effects & Levels. Retrieved from https://my.clevelandclinic.org/health/articles/24555-dht-dihydrotestosterone

[2] Brough, K. R., & Torgerson, R. R. (2017). Hormonal therapy in female pattern hair loss. International Journal of Women's Dermatology, 3(1), 29-35. https://pmc.ncbi.nlm.nih.gov/articles/PMC5419033/

[3] Healthy Aging and Longevity. (2024). Treating female pattern hair loss. Harvard Health Publishing. https://www.health.harvard.edu/healthy-aging-and-longevity/treating-female-pattern-hair-loss

[4] Dr. Szczyt. (2025). How can women effectively deal with androgenetic alopecia?. https://www.drszczyt.pl/en/blog/jak-kobiety-moga-skutecznie-radzic-sobie-z-lysieniem-androgenowym

[5] American Academy of Dermatology Association. (n.d.). Hair loss: Diagnosis and treatment. Retrieved from https://www.aad.org/public/diseases/hair-loss/treatment/diagnosis-treatment

[6] Adil, A., & Godwin, K. (2017). The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 77(1), 136-141.e5. https://www.jaad.org/article/S0190-9622(16)30942-7/fulltext30942-7/fulltext)

[7] Sante Clinics. (2026). Peptides for Hair Growth: A New Approach to Hair Loss. https://santeclinics.com/blog/power-of-peptides-for-hair-growth-new-approach-to-hair-loss

[9] Recellebrate. (n.d.). Peptide Therapy for Hair Regrowth: Androgenetic Alopecia. Retrieved from https://recellebrate.com/blog/peptide-therapy-hair-regrowth/